| 12358928 |
Compounds, compositions and methods |
Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Colin Phillip Leslie, Alfonso Pozzan +2 more |
2025-07-15 |
|
| 12240846 |
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases |
Samuel Kintz, Li Ren |
2025-03-04 |
|
| 12214058 |
Imaging methods using deuterated compounds |
Jan Marik, Simon Williams |
2025-02-04 |
|
| 12171739 |
N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Julie Marie Hicks, Fredrik P. Marmsater, Qian Zhao |
2024-12-24 |
|
| 11858926 |
Inhibiting agents for bruton's tyrosine kinase |
Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Fengmei Zheng +2 more |
2024-01-02 |
$63,477,000 |
| 11840529 |
Substituted pyrimidines as LRKK2 inhibitors |
Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney, Javier de Vicente Fidalgo |
2023-12-12 |
|
| 11834439 |
Compounds, compositions, and methods |
Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney |
2023-12-05 |
|
| 11807638 |
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases |
Samuel Kintz, Li Ren |
2023-11-07 |
|
| 11807649 |
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 |
Samuel Kintz, Li Ren, Qiang Su |
2023-11-07 |
$7,128,000 |
| 11767321 |
5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
Samuel Kintz, Li Ren |
2023-09-26 |
|
| 11591316 |
Compounds, compositions, and methods |
Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney |
2023-02-28 |
|
| 11572356 |
Biaryl inhibitors of Bruton's tyrosine kinase |
Brian T. Hopkins, Bin Ma, Timothy Chan, Lihong Sun, Lei Zhang +3 more |
2023-02-07 |
$222,965,000 |
| 11504440 |
Deuterated compounds |
Jan Marik, Simon Williams |
2022-11-22 |
|
| 11427561 |
IRAK4 inhibiting agents |
Timothy Chan, Kevin M. Guckian, Tracy J. Jenkins, Jermaine Thomas, Jeffrey Vessels +6 more |
2022-08-30 |
$41,858,000 |
| 11427577 |
Inhibiting agents for Bruton's tyrosine kinase |
Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Fengmei Zheng +2 more |
2022-08-30 |
$41,858,000 |
| 11236046 |
Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators |
Huifen Chen, Yanyan Chu, Steven Do, Anthony A. Estrada, Baihua Hu +7 more |
2022-02-01 |
|
| 11214565 |
Compound, compositions, and methods |
Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney, Javier de Vicente Fidalgo |
2022-01-04 |
|
| 11174273 |
Quinazoline analogs as receptor tyrosine kinase inhibitors |
Eli M. Wallace, George T. Topalov, Alexandre Joseph Buckmelter, Qian Zhao |
2021-11-16 |
|
| 11129832 |
Biheteroaryl compounds and uses thereof |
Anthony Estrada, Liting Dong, Kevin X. Chen, Paul Gibbons, Malcolm Huestis +7 more |
2021-09-28 |
|
| 11111235 |
Compounds, compositions, and methods |
Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney |
2021-09-07 |
|
| 11028080 |
Substituted pyrimidines as LRKK2 inhibitors |
Anthony A. Estrada, Jianwen A. Feng, Zachary K. Sweeney, Javier de Vicente Fidalgo |
2021-06-08 |
|
| 10961237 |
Inhibiting agents for Bruton's tyrosine kinase |
Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Fengmei Zheng +2 more |
2021-03-30 |
$305,557,000 |
| 10780073 |
N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
Julie Marie Hicks, Fredrik P. Marmsater, Qian Zhao |
2020-09-22 |
|
| 10766878 |
Sulfonylcycloalkyl carboxamide compounds |
Baihua Hu, Vishal Verma, Matthew Volgraf, Anthony A. Estrada |
2020-09-08 |
|
| 10759783 |
Biaryl inhibitors of Bruton'S tyrosine kinase |
Brian T. Hopkins, Bin Ma, Timothy Chan, Lihong Sun, Lei Zhang +3 more |
2020-09-01 |
$468,791,000 |
